Reflecting these advantages, the 2023 treatment algorithm for type 2 diabetes, published by the Japanese Diabetes Society, recommends GLP-1 RAs for patients with cardiovascular disease or chronic kidney disease, anticipating additional benefits [35, 36]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.